Ischaemic preconditioning: present position and future directions.
Preconditioning the myocardium using short episodes of sublethal ischaemia will delay the onset of necrosis during a subsequent lethal ischaemic insult. This powerful protective adaptation of the myocyte has also been observed in other cell types. The potential for clinical application to benefit patients with a variety of pathological conditions has led to an expansion in our knowledge concerning the pathophysiology of ischemia-reperfusion injury and the regulatory mechanisms underlying cellular metabolism. We feel it is timely to assess the current position in this field and provide a critical appraisal to facilitate future research.
Yellon
D M
DM
Hatter Institute for Cardiovascular Studies, University College London Hospitals, London, UK. s.bush-cavell@ucl.ac.uk
Baxter
G F
GF
Garcia-Dorado
D
D
Heusch
G
G
Sumeray
M S
MS
D000818:Animals; D006801:Humans; D019194:Ischemic Preconditioning; D019157:Ischemic Preconditioning, Myocardial; D017202:Myocardial Ischemia / Q000378:metabolism*; D015428:Myocardial Reperfusion Injury / Q000378:metabolism / Q000517:prevention & control*; D009206:Myocardium / Q000378:metabolism*; D015221:Potassium Channels / Q000378:metabolism; D011493:Protein Kinase C / Q000378:metabolism; D018047:Receptors, Purinergic P1 / Q000378:metabolism; D012106:Research; D015398:Signal Transduction
D015221:Potassium Channels; D018047:Receptors, Purinergic P1; D011493:Protein Kinase C